An Open-Label, Drug-Drug Interaction Study to Evaluate the Effect of Paliperidone Extended-Release on the Steady-State Pharmacokinetics of Valproic Acid in Clinically Stable Subjects With Schizophrenia, Bipolar I Disorder or Schizoaffective Disorder.
Phase of Trial: Phase I
Latest Information Update: 28 Sep 2015
At a glance
- Drugs Paliperidone (Primary) ; Valproate semisodium
- Indications Bipolar I disorders; Schizoaffective disorder; Schizophrenia
- Focus Pharmacokinetics
- Sponsors Janssen Research & Development
- 10 Jun 2017 Biomarkers information updated
- 28 Sep 2015 Results published in the Journal of Clinical Pharmacology.
- 20 Mar 2012 Actual initiation date changed from 1 Mar 2009 to 1 Feb 2009 as reported by ClinicalTrials.gov.